Top Markets
Coin of the day
Theralase Technologies Inc. Theralase Technologies Inc.

Theralase Technologies Inc.

TLT
株式のランク #26101
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages... Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of light activated photo dynamic compounds and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. The company operates through Drug Division and Device Division segments. It designs, develops, manufactures, and markets super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II clinical trial for the treatment of Bacillus Calmette Guérin-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ. Further, it researches, develops, manufactures, and distributes controller-less cool laser therapy systems comprising TLC-900, TLC-300, and TLC-100 to healthcare practitioners primarily for the healing of pain. The company has a collaboration with the National Microbiology Laboratory, a Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. Theralase Technologies Inc. is based in Toronto, Canada.
株価
$0.14678738
時価総額
$43.40M
変化(1日)
14.29%
変化(1年)
-7.44%
CA
取引 Theralase Technologies Inc. (TLT)

カテゴリー

Theralase Technologies Inc.(TLT)のP/B比率
2026 時点のP/B比率 TTM: 0
Theralase Technologies Inc. の最新の財務報告および株価によると、現在のP/B比率(TTM)は 0 です。2026 年末時点でのP/B比率は 0 でした。
Theralase Technologies Inc. の P/B 比率の履歴(2026 ~ 2026)
各年末時点のP/B比率
P/B比率 変化
提供された日付のデータは十分ではありません。
同業他社のP/B比率
企業 P/B比率 P/B比率の差
3.7944 -
US
5.423 -
US
2.0146 -
IE
3.072 -
US
- -
DE